Recent advances in female sexual dysfunction.
Female sexuality has received little scientific study. Recently, increased interest in this field has generated new research in the epidemiology, pathophysiology, and pharmacotherapy of female sexual dysfunction (FSD). A new FSD classification system has been proposed. Although sexual difficulties are highly prevalent among women, the degree of associated distress is unknown. Risk factors for FSD are probably both psychologic and physiologic. Aging or menopause is associated with lubrication difficulties, which can be treated with hormone replacement. Hysterectomy seems more likely to result in improvement rather then deterioration of sexual functioning. Depression may be a predictor of sexual dysfunction after hysterectomy. Vasoactive agents are currently being evaluated as treatment for female sexual arousal disorder. The most important advance in the study of female sexual function is the recent surge of interest in this relatively unexplored field.
Davis
A R
AR
Department OB/GYN and Urology, Columbia University College of Physicians & Surgeons, PH-16, Room 80, 630 West 168th Street, New York, NY 10032, USA. daviann@cpmc3.cpmc.columbia.edu
D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D012307:Risk Factors; D020018:Sexual Dysfunctions, Psychological / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D014665:Vasodilator Agents